PRESS RELEASES

• JULY 23, 2008 - Bradmer Initiates Enrollment In Phase III GLASS-ART Trial In Primary Glioblastoma Multiforme 
  
  
• JULY 17, 2008 - Bradmer Reports Progression Free Survival Data Fom Previous Phase II Glioblastoma Multiforme Trials  - PFS data from Neuradiab™ compares favorably to data from other technologies -
  
  
• JUNE 3, 2008 - Bradmer Receives FDA Approval To Proceed With Phase III Clinical Trial 
  
  
• MAY 9, 2008 - Bradmer Announces 2008 First Quarter Operational And Financial Results
  
  
• APRIL 2, 2008 - Bradmer Announces New Additions To Management Team
  
  
• APRIL 1, 2008 - Bradmer appoints Robert Tessarolo To Board of Directors
  
  
• MARCH 12, 2008 - Bradmer Announces 2007 Fourth Quarter And Fiscal Year Operational And Financial Results 
  
  
• MARCH 5, 2008 - Notice Of Bradmer Pharmaceuticals Conference Call
  
  
• FEBRUARY 26, 2008 - Bradmer Announces Phase II Results Published In Newly Diagnosed Glioblastoma Which Demonstrate Improved Survival And Support Upcoming Phase III Study
  
  
• FEBRUARY 8, 2008 - Bradmer To Present At The 10th Annual BIO CEO & Investor Conference
  
  
• DECEMBER 12, 2007 - Bradmer Announces Additions To Scientific Advisory Board
  
  
• DECEMBER 10, 2007 - Bradmer Medical Isotope Supply For Phase III Trial Secure
  
  
• NOVEMBER 13, 2007 - Bradmer Announces 2007 Third Quarter Operational and Financial Results
  
  
• NOVEMBER 13, 2007 - Bradmer Announces Change To Board of Directors 
  
  
• OCTOBER 31, 2007 - Bradmer to Present at Rodman & Renshaw Healthcare Conference
  
  
• OCTOBER 14, 2007 - Bradmer Provides Phase III Neuradiab Trial Update and Guidance
  
  
• OCTOBER 3, 2007 - Bradmer Announces Management Changes
  
  
• SEPTEMBER 12, 2007 - Bradmer Appoints Paul Van Damme Chief Financial Officer
  
  
• AUGUST 15, 2007 - Bradmer Announces Dr. Phil Gold To Join Board of Directors 
  
  
• AUGUST 8, 2007 - Bradmer Announces 2007 Second Quarter Operational and Financial Results 
  
  
• AUGUST 8, 2007 - Bradmer Announces Senior Management Appointments
  
  
• JULY 10, 2007 - Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings
  
  
• JUNE 22, 2007 -  Bradmer Completes $23.1 Million Offering
  
  
• MAY 30, 2007: Bradmer Announces $21,600,000 Bought Deal Offering
  
  
• MAY 10, 2007: Bradmer Pharmaceuticals Announces 2007 First Quarter Operational and Financial Results
  
  
• MAR 23, 2007: Bradmer Pharmaceuticals Hires Vice President of Medical Affairs and Opens Montreal Office
  
  
• MAR 1, 2007: Bradmer Announces 2006 Fourth Quarter and Fiscal Year Operational and Financial Results
  
  
• FEB 14, 2007:  Bradmer Executive to Present at the Technology Transfer For Biopharmaceuticals Conference
  
  
  2006 Press Releases
  
  
  * Note: Links will open in PDF format
  
  
  Readers are advised that information posted to the Bradmer Pharmaceuticals website was deemed accurate at the time it was posted, but may be superseded by subsequent disclosures.